drugset / Trial / NCT00059839

Comparison of Two Combination Chemotherapy Regimens With Either Vincristine or Vinblastine in Treating Patients With Advanced Anaplastic Large Cell Lymphoma

NCT00059839

RandomizedParallel-groupOpen-labelTreatment

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. It is not yet known if combination chemotherapy with vinblastine is more effective than combination chemotherapy with vincristine in treating advanced anaplastic large cell lymphoma. PURPOSE: Randomized phase III trial to compare the effectiveness of two combination chemotherapy regimens with either vinblastine or vincristine in treating patients who have newly diagnosed advanced anaplastic large cell lymphoma.

Timeline

Start
2003-11
Primary completion
2009-12
Completion
2014-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Vinblastine Small molecule 4 mg/m2 Intravenous
Subject Vincristine Small molecule 1.5 mg/m2 Intravenous
Background Doxorubicin Other / unclassified 30 mg/m2 Intravenous
Background MERCAPTOPURINE ANHYDROUS Small molecule 225 mg/m2 Oral
Background Methotrexate Small molecule 60 mg/m2 Intrathecal
Background Prednisone Other / unclassified 120 mg/m2 Oral

Indications